Anticoagulant options in atrial fibrillation: When new treatments become standard practice

    loading  Checking for direct PDF access through Ovid

Abstract

Direct oral anticoagulants (DOACs) have expanded options for treating patients with atrial fibrillation (AF). However, DOACs are not warfarin substitutes, and NPs need to be aware of the difference. DOACs are first-line agents when treating AF, yet warfarin has not been replaced. Individualized patient characteristics drive current guidelines.

Related Topics

    loading  Loading Related Articles